910 results match your criteria Hepatology International [Journal]


Mini-review: end-points for drug treatment in NASH.

Authors:
Leon A Adams

Hepatol Int 2019 Feb 19. Epub 2019 Feb 19.

M503, Medical School, QEII Medical Centre, University of Western Australia, Nedlands, Perth, WA, 6009, Australia.

Non-alcoholic steatohepatitis (NASH) is an increasingly common cause of cirrhosis, hepatocellular carcinoma, and liver-related death (LRD). Consequently, there is a critical need for effective drug therapy that improves clinically relevant end-points. Hepatic steatosis assessed by magnetic resonance imaging-proton density fat fraction is increasingly used in the early phase trials examining drugs with anti-steatotic effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-019-09935-6DOI Listing
February 2019

Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?

Hepatol Int 2019 Feb 13. Epub 2019 Feb 13.

Diagnostic Radiology, Zagazig University, Zagazig, Egypt.

Background: Medical treatment of decompensated cirrhosis due to hepatitis C virus (HCV) remains a clinical challenge even in the era of direct-acting antiviral drugs (DAAs). We evaluated the efficacy and safety of DAAs in the management of HCV genotype 4-related decompensated cirrhosis.

Methods: The study included a treatment group (n = 160) composed of HCV patients with decompensated cirrhosis who received DAAs for 3 months and a matched control group (n = 80) who preferred not to receive DAAs, follow-up was for 24-31 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-019-09933-8DOI Listing
February 2019
1 Read

Serum ferritin as a biomarker for NAFLD: ready for prime time?

Hepatol Int 2019 Feb 9. Epub 2019 Feb 9.

Liver Care Network and Organ Care Research, Swedish Medical Center, 1124 Columbia Street, Suite 600, Seattle, WA, 98104, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12072-019-09934-7
Publisher Site
http://dx.doi.org/10.1007/s12072-019-09934-7DOI Listing
February 2019
2 Reads

Influence of proton pump inhibitors on microbiota in chronic liver disease patients.

Hepatol Int 2019 Feb 8. Epub 2019 Feb 8.

Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, 466-8550, Japan.

Background: Current knowledge suggests that proton pump inhibitors (PPIs) are associated with an increased risk of hepatic encephalopathy (HE) and spontaneous bacterial peritonitis (SBP). These conditions and PPI use are related to gut microbiota. The aim of this study is to research the changes in gut microbiota caused by PPI in patients with chronic liver disease. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12072-019-09932-9
Publisher Site
http://dx.doi.org/10.1007/s12072-019-09932-9DOI Listing
February 2019
2 Reads

The impact of national viral hepatitis therapy program and hepatitis B vaccination program on mortality from acute and chronic viral hepatitis in Taiwan.

Authors:
Shih-Yung Su

Hepatol Int 2019 Jan 31. Epub 2019 Jan 31.

Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Rm. 541, No. 17, Xuzhou Rd, Taipei, 100, Taiwan.

Background: In Taiwan, the national hepatitis B virus vaccination program and national viral hepatitis therapy program were implemented to control the infections of hepatitis viruses and their progressive illnesses. Studies have evaluated the impacts of two national health programs on many liver-related diseases, but not on acute and chronic viral hepatitis. The purpose of this study was to evaluate the impact on the mortality of acute and chronic viral hepatitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-019-09931-wDOI Listing
January 2019
5 Reads

Correction to: Antifibrotics in liver disease: are we getting closer to clinical use?

Hepatol Int 2019 Jan;13(1):40-41

Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, Box 1123, New York, NY, 10029, USA.

The original article can be found online. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-09924-1DOI Listing
January 2019

Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016.

Hepatol Int 2019 Jan 29. Epub 2019 Jan 29.

Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA, USA.

Background And Aim: Advanced fibrosis associated with nonalcoholic fatty liver disease (NAFLD) has been reported to have a higher risk of hepatic and non-hepatic mortality. We aim to study the recent trends in the prevalence of NAFLD-related advanced fibrosis in a large population sample.

Methods: Cross-sectional data from 28,739 participants in the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2016 were utilized. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12072-018-09926-z
Publisher Site
http://dx.doi.org/10.1007/s12072-018-09926-zDOI Listing
January 2019
4 Reads
2.468 Impact Factor

Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?

Hepatol Int 2019 Jan 24. Epub 2019 Jan 24.

Division of Transplantation, Department of Surgery, College of Medicine, Pennsylvania State University, Mail Code H062, 500 University Drive, PO Box 850, Hershey, PA, 17033-0850, USA.

Background: Recently, a controversy has emerged: is the rate of recurrence of hepatocellular carcinoma (HCC) higher following treatment of hepatitis C virus (HCV) with direct-acting antiviral (DAA) therapy? However, the risk of HCC recurrence has not been studied in liver transplant (LTx) recipients who received DAA therapy. The aim of the present study is to compare the rate of HCC recurrence in LTx recipients who did or did not receive DAA therapy.

Patients And Methods: Sixty-three patients received LTx with HCC. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12072-019-09930-x
Publisher Site
http://dx.doi.org/10.1007/s12072-019-09930-xDOI Listing
January 2019
1 Read
2.468 Impact Factor

The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting.

Hepatol Int 2019 Jan 22. Epub 2019 Jan 22.

Department of Gastroenterology, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu, 400-8506, Yamanashi, Japan.

Background/purpose: Lenvatinib (an inhibitor of vascular endothelial growth factor (GF) receptors 1-3, fibroblast GF receptors 1-4, platelet-derived GF receptor α, rearranged during transfection, and stem cell factor receptor) was non-inferior to sorafenib in a phase 3 (REFLECT) trial of advanced hepatocellular carcinoma. This study examined the efficacy and safety of lenvatinib in a real-world setting.

Methods: This was a retrospective, multicenter, observational study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-019-09929-4DOI Listing
January 2019
2.468 Impact Factor

Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection.

Hepatol Int 2019 Jan 22. Epub 2019 Jan 22.

Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road 102, Hong Kong, China.

Background And Aim: Mac-2-binding protein glycosylation isomer (M2BPGi) is a novel serum diagnostic marker for liver fibrosis in various liver diseases. We aimed to evaluate its role in assessment of liver fibrosis in chronic hepatitis B infection (CHB) with reference to liver stiffness measurement (LSM).

Methods: CHB patients with LSM by transient elastography technology and retrievable serum samples were recruited. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12072-019-09928-5
Publisher Site
http://dx.doi.org/10.1007/s12072-019-09928-5DOI Listing
January 2019
7 Reads

Chinese guidelines on the management of ascites and its related complications in cirrhosis.

Hepatol Int 2019 Jan 18;13(1):1-21. Epub 2019 Jan 18.

Department of Pathogen Biology, Peking University Health Science Center, Beijing, China.

The Chinese Society of Hepatology developed the current guidelines for the Management of Ascites and Its Related Complications in Cirrhosis based on the published evidences and the panelists' consensus. The guidelines provided recommendations for the diagnosis and management of cirrhotic ascites emphasizing a step-wise approach with the first-, second-, and third-line therapy. For refractory ascites, vasoconstrictors and albumin are recommended for splanchnic vasodilation and selective vasopressin (V2) receptor antagonists for moderate-to-severe hyponatremia. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12072-018-09923-2
Publisher Site
http://dx.doi.org/10.1007/s12072-018-09923-2DOI Listing
January 2019
9 Reads

Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd-Chiari syndrome on warfarin.

Hepatol Int 2019 Jan 8. Epub 2019 Jan 8.

Department of Gastroenterology, Seth GS Medical College and KEM Hospital, Mumbai, 400012, India.

Introduction: Anticoagulation is universally recommended in Budd-Chiari syndrome [BCS]. Vitamin K epoxide reductase complex 1 (VKORC1) and CYP2C9 are involved in the metabolism of warfarin. The present study was done to assess whether these mutations are associated with the risk of bleeding in patients with BCS receiving warfarin. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12072-018-9922-6
Publisher Site
http://dx.doi.org/10.1007/s12072-018-9922-6DOI Listing
January 2019
10 Reads

Liver damage related to immune checkpoint inhibitors.

Hepatol Int 2019 Jan 3. Epub 2019 Jan 3.

Department of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University, 377-2 Ohno-higashi, Osaka-sayama, Osaka, 589-8511, Japan.

Recently, immune checkpoint inhibitors are becoming one of the key agents of systemic treatment of cancer. The anti-cancer mechanism of this type of agent is totally different from that of conventional therapies; blockade of regulatory receptors and ligand of immune checkpoint molecules arose anti-tumor immunity with durable response. However, owing to its unique action to host immune system, immune checkpoint inhibitors sometimes induce immune-related adverse events (irAEs) which has not been observed for conventional chemotherapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9921-7DOI Listing
January 2019
1 Read

Immunological cure of HBV infection.

Hepatol Int 2019 Jan 2. Epub 2019 Jan 2.

Department of Medicine II, University Hospital Freiburg, Faculty of Medicine, Hugstetter Strasse 55, 79106, Freiburg, Germany.

Chronic hepatitis B virus (HBV) infection is a major global health burden and cure is rarely achieved by current antiviral therapies. Therefore, there is an urgent need for new therapeutic options. Immune modulation with the goal to restore dysfunctional HBV-specific immunity is an interesting target for new therapeutic strategies. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12072-018-9912-8
Publisher Site
http://dx.doi.org/10.1007/s12072-018-9912-8DOI Listing
January 2019
1 Read

Laser capture microdissection: techniques and applications in liver diseases.

Hepatol Int 2019 Jan 1. Epub 2019 Jan 1.

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), C/Rosselló, 149-153, Third Floor, 08036, Barcelona, Spain.

Routine transcriptomic and proteomic analysis are usually performed at a whole organ or tissue level. These approaches provide an average readout of all cell types present within the tissue but do not allow differentiating the profile of specific cell populations. Laser capture microdissection (LCM) constitutes an excellent tool to isolate cell populations or areas of interest within a tissue. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9917-3DOI Listing
January 2019

Goals and targets for personalized therapy for HCC.

Hepatol Int 2019 Jan 1. Epub 2019 Jan 1.

Division of Gastroenterology, Hepatology, and Nutrition, University of Chicago Medical Center, 5841 S. Maryland Avenue, Chicago, IL, 60637, USA.

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide and its incidence continues to rise. While cirrhosis underlies most cases of HCC, many molecular pathways are implicated in HCC carcinogenesis, including the TERT promoter mutation, Wnt/β-catenin, P53, Akt/mTOR, vascular endothelial growth factor receptor (VEGFR), and endothelial growth factor receptor (EGFR)/RAS/MAPK pathways. While the most widely used staging and treatment algorithm for HCC-the Barcelona Clinic Liver Cancer (BCLC) system-does not recommend systemic molecular therapy for early HCC, a variety of treatment options are available depending upon the stage of HCC at diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9919-1DOI Listing
January 2019

Plasminogen activator inhibitor 2 (PAI2) inhibits invasive potential of hepatocellular carcinoma cells in vitro via uPA- and RB/E2F1-related mechanisms.

Hepatol Int 2019 Jan 1. Epub 2019 Jan 1.

Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, 100730, China.

Background: Plasminogen activator inhibitor 2 (PAI2) has been shown to be associated with invasive phenotypes and prognosis in hepatocellular carcinoma (HCC). However, its biological roles and underlying mechanisms in invasion of HCC have not been explored. The present study aimed to address the issues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9920-8DOI Listing
January 2019

Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort).

Hepatol Int 2019 Jan 6;13(1):66-74. Epub 2018 Dec 6.

Infectious Diseases Unit, Department of Mental Health and Public Medicine, University of Campania Luigi Vanvitelli, Caserta, Italy.

Background: Direct-acting antivirals (DAAs) are safe and effective for the treatment of HCV infection. However, data regarding their efficacy in patients with Child-Pugh B cirrhosis are scarce and their capability in improving liver function is debated. The aim of our study was to assess the clinical benefits of treatment with DAA in subjects with Child-Pugh B cirrhosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9914-6DOI Listing
January 2019

Use of anti-platelet agents in the prevention of hepatic fibrosis in patients at risk for chronic liver disease: a systematic review and meta-analysis.

Hepatol Int 2019 Jan 12;13(1):84-90. Epub 2018 Dec 12.

Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.

Background And Aims: While the association between platelet activation and hepatic fibrosis has been previously demonstrated in animal studies; the utility of anti-platelet agents in reversing the progression of hepatic fibrosis requires further review. Utilizing systematic review methods, we provide to our knowledge the first meta-analysis combining evidence from all studies aimed to establish the effect of anti-platelet agents in the prevention of hepatic fibrosis.

Methods: We searched Medline, EMBASE and PubMed databases from inception to October 2018 to identify all studies aimed at evaluating the role of anti-platelet agents in the prevention of hepatic fibrosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9918-2DOI Listing
January 2019
2.468 Impact Factor

APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?

Hepatol Int 2018 Dec 11. Epub 2018 Dec 11.

Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu-shi, Yamanashi, 400-8506, Japan.

Chronic hepatitis C virus (HCV) infection is common among patients with chronic kidney disease (CKD) and those on hemodialysis due to nosocomial infections and past blood transfusions. While a majority of HCV-infected patients with end-stage renal disease are asymptomatic, some may ultimately experience decompensated liver diseases and hepatocellular carcinoma. Administration of a combination of elbasvir/grazoprevir for 12 weeks leads to high sustained virologic response (SVR) rates in patients with HCV genotypes (GTs) 1a, 1b or 4 and stage 4 or 5 CKD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9915-5DOI Listing
December 2018
2.468 Impact Factor

Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka.

Hepatol Int 2018 Dec 11. Epub 2018 Dec 11.

Department of Medicine, Faculty of Medicine, University of Kelaniya, Thalagolla Road, P O Box 6, Ragama, GQ, 11010, Sri Lanka.

Introduction: While patients with non-alcoholic fatty liver disease (NAFLD) are mostly overweight or obese, some are lean.

Methods: In a community-based follow-up study (baseline and follow-up surveys performed in 2007 and 2014), we investigated and compared the clinical characteristics, body composition, metabolic associations and outcomes, and other risk factors among individuals with lean (BMI < 23 kg/m) NAFLD, non-lean (BMI ≥ 23 kg/m) NAFLD and those without NAFLD. To investigate associations of selected genetic variants, we performed a case-control study between lean NAFLD cases and lean non-NAFLD controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9916-4DOI Listing
December 2018

Precision-cut liver slices: a versatile tool to advance liver research.

Hepatol Int 2019 Jan 4;13(1):51-57. Epub 2018 Dec 4.

Institute of Hepatology London, Foundation for Liver Research, London, UK.

Human precision-cut liver slices represent a robust and versatile ex vivo model which retains the complex and multi-cellular histoarchitecture of the hepatic environment. As such, they represent an ideal model to investigate the mechanisms of liver injury and for the identification of novel therapeutic targets. Schematic overview to highlight the utility of precision-cut liver slices as a relevant and versatile ex-vivo model of liver disease. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12072-018-9913-7
Publisher Site
http://dx.doi.org/10.1007/s12072-018-9913-7DOI Listing
January 2019
6 Reads

DAMPs and sterile inflammation in drug hepatotoxicity.

Hepatol Int 2019 Jan 24;13(1):42-50. Epub 2018 Nov 24.

Department of Emergencies and Critical Care, Oslo University Hospital, Nydalen, PO Box 4950, 0424, Oslo, Norway.

Drug hepatotoxicity is the leading cause of acute liver failure (ALF) in the developed countries. The early diagnosis and treatment are still problematic, and one important reason is the lack of reliable mechanistic biomarkers and therapeutic targets; therefore, searching for new biomarkers and therapeutic targets is urgent. Drug hepatotoxicity induces severe liver cells damage and death. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9911-9DOI Listing
January 2019
1 Read

Activity of IL-12/15/18 primed natural killer cells against hepatocellular carcinoma.

Hepatol Int 2019 Jan 22;13(1):75-83. Epub 2018 Nov 22.

Faculty of Medicine, Southampton General Hospital, University of Southampton, Tremona Road, Southampton, SO16 6YD, UK.

Background: Hepatocellular carcinoma (HCC) is common, but remains difficult to treat. Natural killer (NK) cells are cells of the innate immune system that have potent anti-cancer activity. Recent work has shown that stimulation with IL-12/15/18 leads to the generation of NK cells with enhanced functional and putative "memory" properties. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9909-3DOI Listing
January 2019
5 Reads

The effects of curcumin on the metabolic parameters of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.

Hepatol Int 2018 Nov 16. Epub 2018 Nov 16.

Department of Gastroenterology, The Second Affiliated Hospital, Xi'an Jiaotong University, No. 157, Xi Wu Road, Xi'an, Shanxi, People's Republic of China.

Aims: Evidence indicates that curcumin seems to improve outcomes in non-alcoholic fatty liver disease (NAFLD). A meta-analysis was performed to evaluate the effects of curcumin inNAFLD.

Methods: We searched PubMed, EMBASE, and the Cochrane Library from inception through March 2018 to identify randomized controlled trials (RCTs) evaluating the role of curcumin inNAFLD. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12072-018-9910-x
Publisher Site
http://dx.doi.org/10.1007/s12072-018-9910-xDOI Listing
November 2018
8 Reads
2.468 Impact Factor

Systematic review: diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis.

Hepatol Int 2019 Jan 15;13(1):91-101. Epub 2018 Nov 15.

National Clinical Research Center of Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.

Background And Aims: Non-invasive fibrosis assessment has been highly recommended in many liver diseases. However, comparative diagnostic accuracy of laboratory markers, ultrasound and magnetic resonance elastography (MRE) for fibrosis in autoimmune hepatitis (AIH) patients has not been established.

Methods: Medline, Embase and Cochrane Library were searched. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12072-018-9907-5
Publisher Site
http://dx.doi.org/10.1007/s12072-018-9907-5DOI Listing
January 2019
10 Reads

Metal, magnet or transplant: options in primary sclerosing cholangitis with stricture.

Authors:
Jawad Ahmad

Hepatol Int 2018 Nov 14;12(6):510-519. Epub 2018 Nov 14.

Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease of the biliary tree of unknown etiology leading to stricturing and dilation. There is currently no effective medical therapy for PSC and liver transplantation (LT) remains the ultimate treatment for severe disease defined as repeated episodes of cholangitis, decompensated biliary cirrhosis or in exceptional cases, cholangiocarcinoma (CCA). Patients often present with a "dominant" stricture and the therapeutic endoscopist plays an important role in management to improve biliary patency using a variety of techniques that involve sampling, balloon dilation and temporary stenting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9906-6DOI Listing
November 2018
2 Reads

Risks of hepatocellular carcinoma and cirrhosis-associated complications in patients with rheumatoid arthritis: a 10-year population-based cohort study in Taiwan.

Hepatol Int 2018 Nov 14;12(6):531-543. Epub 2018 Nov 14.

School of Medicine, Tzu Chi University, Hualien, Taiwan, ROC.

Background/purpose: Although rheumatoid arthritis (RA) has been linked to several important malignancies, data for the risks of hepatocellular carcinoma (HCC) in patients with RA are scarce. We aimed to examine the risk of HCC and cirrhosis-associated complications and the use of biologics in a national representative RA sample in Taiwan.

Methods: All study subjects aged ≥ 18 years in the Taiwan National Health Insurance program between January 1, 2000, and December 31, 2009 were enrolled. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12072-018-9905-7
Publisher Site
http://dx.doi.org/10.1007/s12072-018-9905-7DOI Listing
November 2018
10 Reads

Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals.

Hepatol Int 2018 Nov 13;12(6):544-551. Epub 2018 Nov 13.

Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.

Background/aims: Liver fibrosis determined hepatocellular carcinoma (HCC) occurrence in chronic hepatitis C patients with sustained virological response (SVR). We aimed to determine whether post-treatment fibrotic modification overwhelmed pretreatment fibrotic status in terms of long-term HCC prediction.

Methods: 265 SVR patients with paired biopsies before and after antiviral therapy were enrolled for analysis of the association of fibrotic changes with HCC. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12072-018-9908-4
Publisher Site
http://dx.doi.org/10.1007/s12072-018-9908-4DOI Listing
November 2018
10 Reads

New generation cancer therapy: right direction for sure with some uncertainty.

Authors:
Yoshiyuki Ueno

Hepatol Int 2019 Jan 7;13(1):22-24. Epub 2018 Nov 7.

Gastroenterology, Yamagata University Faculty of Medicine, 2-2-2 Iidanishi, Yamagata, 9909585, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9904-8DOI Listing
January 2019

Identifying barriers to treatment of HCV in the primary care setting.

Hepatol Int 2019 Jan 30;13(1):58-65. Epub 2018 Oct 30.

Department of Medicine, Dunedin School of Medicine, University of Otago, PO Box 913, Dunedin, 9054, New Zealand.

Objective: To identify practice, attitudes, and potential barriers to treatment of Hepatitis C to primary care practitioners.

Design: A postal survey of general practitioners in New Zealand.

Setting: Nationwide postal survey to all general practitioners in New Zealand. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9902-xDOI Listing
January 2019

How to identify the need for liver transplantation in pediatric acute-on-chronic liver failure?

Hepatol Int 2018 Nov 19;12(6):552-559. Epub 2018 Oct 19.

Department of Pediatric Hepatology, Institute of Liver and Biliary Sciences, New Delhi, 110070, India.

Objectives: The objectives of the study were to evaluate the prognostic value of APASL ACLF Research Consortium-Acute-on-chronic liver failure (AARC-ACLF) score against the current prognostic models in pediatric ACLF and to assess the role of pediatric modifications of AARC-ACLF score and chronic liver failure-sequential organ failure assessment (CLIF-SOFA) score.

Methods: All children between 1 and 18 years of age satisfying the APASL definition of ACLF were included in the study. All the prognostic scores were calculated retrospectively from hospital records. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9901-yDOI Listing
November 2018
2.470 Impact Factor

Fatty liver checkmates hepatitis B virus.

Hepatol Int 2018 Sep 12;12(5):387-389. Epub 2018 Oct 12.

Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences (ILBS), D1 Block, Vasant Kunj, New Delhi, 110070, India.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12072-018-9903-9
Publisher Site
http://dx.doi.org/10.1007/s12072-018-9903-9DOI Listing
September 2018
1 Read

Hepatitis B-positive health-care workers: why they should not switch to non-exposure-prone jobs.

Authors:
Ankur Jindal

Hepatol Int 2018 Nov 11;12(6):520-522. Epub 2018 Oct 11.

Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9899-1DOI Listing
November 2018

Antifibrotics in liver disease: are we getting closer to clinical use?

Hepatol Int 2019 Jan 9;13(1):25-39. Epub 2018 Oct 9.

Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, Box 1123, New York, NY, 10029, USA.

The process of wound healing in response to chronic liver injury leads to the development of liver fibrosis. Regardless of etiology, the profound impact of the degree of liver fibrosis on the prognosis of chronic liver diseases has been well demonstrated. While disease-specific therapy, such as treatments for viral hepatitis, has been shown to reverse liver fibrosis and cirrhosis in both clinical trials and real-life practice, subsets of patients do not demonstrate fibrosis regression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9897-3DOI Listing
January 2019

Budd-Chiari syndrome: a focussed and collaborative approach.

Hepatol Int 2018 Nov 8;12(6):483-486. Epub 2018 Oct 8.

Department of Hepatology, Institute of Liver and Biliary Sciences, D-1, Vasant Kunj, New Delhi, 110070, India.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12072-018-9900-z
Publisher Site
http://dx.doi.org/10.1007/s12072-018-9900-zDOI Listing
November 2018
4 Reads

Small intestinal bacterial overgrowth in cirrhosis: systematic review and meta-analysis.

Hepatol Int 2018 Nov 4;12(6):567-576. Epub 2018 Oct 4.

Sechenov University, Pogodinskaya Str., 1, bld. 1, 119435, Moscow, Russian Federation.

Background: Small intestinal bacterial overgrowth (SIBO) was detected in cirrhosis in many studies. The aim is to perform a systematic review and meta-analysis on the prevalence of SIBO in cirrhosis and on the relationship of SIBO with features of cirrhosis.

Methods: PUBMED search (until 14 January 2018) was performed. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12072-018-9898-2
Publisher Site
http://dx.doi.org/10.1007/s12072-018-9898-2DOI Listing
November 2018
9 Reads

Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection.

Hepatol Int 2018 Nov 21;12(6):523-530. Epub 2018 Sep 21.

Department of Gastroenterology, Yamanashi Central Hospital, Kofu, Yamanashi, Japan.

Background: Although direct-acting antiviral (DAA) developments make most of hepatitis C virus (HCV) infection curable, some HCV patients develop hepatocellular carcinoma (HCC) after curative treatment of HCV. There is much dispute whether the rapid clearance of the virus enhances the HCC development. In advance of the dispute, we should make clear the characteristics of the patients with very early occurrence and recurrence of HCC after DAA therapy because it was still unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9895-5DOI Listing
November 2018
2 Reads

A changing paradigm: management and treatment of the HCV/HIV-co-infected patient.

Hepatol Int 2018 Nov 20;12(6):500-509. Epub 2018 Sep 20.

Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA.

Hepatitis C virus (HCV) treatment in HIV/HCV co-infected individuals has renewed relevance given the ongoing opioid crisis and rise of new HIV and HCV infections associated with injection drug use. Patients co-infected with HIV and HCV demonstrate increased rates of hepatic fibrosis, progression to liver failure, and liver-related mortality. HIV co-infection does not impact outcomes of current HCV treatments, and patients should be treated the same as HCV mono-infected persons, though attention to drug:drug interactions is required. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9896-4DOI Listing
November 2018
1 Read

Metabolic effects of reduced growth hormone action in fatty liver disease.

Hepatol Int 2018 Sep 11;12(5):474-481. Epub 2018 Sep 11.

Department of Internal Medicine I, Medical University Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.

Background: Adult growth hormone (GH) deficiency is associated with fatty liver disease and shows several features of the metabolic syndrome. Vice versa obesity is characterized as a state of low GH function. Here, we aimed to define the role of hepatic GH signaling and its metabolic consequences in non-alcoholic fatty liver disease. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12072-018-9893-7
Publisher Site
http://dx.doi.org/10.1007/s12072-018-9893-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208861PMC
September 2018
18 Reads

Approach and management of dysnatremias in cirrhosis.

Hepatol Int 2018 Nov 10;12(6):487-499. Epub 2018 Sep 10.

Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Policlinico S. Orsola-Malpighi, Via Albertoni, 15, 40138, Bologna, Italy.

Hypervolemic (dilutional) hyponatremia is the most common dysnatremia in cirrhosis, with a prevalence close to 50% in patients with ascites, while hypovolemic hyponatremia occurs in a minority of cases. Hyponatremia carries a poor prognosis, being associated with increased mortality and reduced survival after liver transplantation. Hypernatremia is rarer and is also associated with an adverse prognosis. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12072-018-9894-6
Publisher Site
http://dx.doi.org/10.1007/s12072-018-9894-6DOI Listing
November 2018
6 Reads

Tolerable and curable treatment in HIV/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China.

Hepatol Int 2018 Sep 10;12(5):465-473. Epub 2018 Sep 10.

Research and Treatment Center of Infectious Diseases, Beijing 302 Hospital, 100, Western 4th Ring Middle Road, Beijing, 100039, China.

Objective: No brand direct-acting antiviral agents (DAAs) are available for treatment of HIV-1/HCV co-infected patients in China. This study aimed to observe the therapeutic efficacy and safety of generic DAAs for affected Chinese patients.

Design: Real-world setting to elucidate whether DAAs were tolerated and effective in HIV-1/HCV co-infected patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9891-9DOI Listing
September 2018
3 Reads
2.470 Impact Factor

Serum ferritin level is associated with liver steatosis and fibrosis in Korean general population.

Hepatol Int 2018 Sep 4. Epub 2018 Sep 4.

Departments of Preventive Medicine, School of Medicine, Kyung Hee University, Seoul, Republic of Korea.

Background: Elevation of serum ferritin levels is frequently observed in non-alcoholic fatty liver disease (NAFLD) patients. Our study aims to examine the association between serum ferritin levels and NAFLD in Korean population.

Methods And Results: A total of 25,597 participants were selected from Korean National Health and Nutritional Examination Surveys 2007-2012. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9892-8DOI Listing
September 2018

Single-nucleotide rs738409 polymorphisms in the PNPLA3 gene are strongly associated with alcoholic liver disease in Han Chinese males.

Hepatol Int 2018 Sep 21;12(5):429-437. Epub 2018 Aug 21.

Department of Clinical Laboratory, The First Hospital of Jilin University, Jilin, 130021, China.

Objective: Alcoholic liver disease (ALD) is a chronic liver disorder caused by the consumption of large amounts of alcohol. Genome-wide association studies have recently confirmed that polymorphisms in PNPLA3 predispose individuals to ALD and have identified risk loci of MBOAT7 and TM6SF2 in persons of European descent. However, the association with alcoholic liver damage has not been evaluated thus far in a Han Chinese population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9889-3DOI Listing
September 2018
1 Read

Management of acute-on-chronic liver failure: an algorithmic approach.

Hepatol Int 2018 Sep 16;12(5):402-416. Epub 2018 Aug 16.

Department of Hepatology and Liver Transplant, Institute of Liver and Biliary Sciences, D-1, VasantKunj, New Delhi, 110070, India.

Acute-on-chronic liver failure (ACLF) is a distinct syndrome of liver failure in a patient with chronic liver disease presenting with jaundice, coagulopathy and ascites and/or hepatic encephalopathy, developing following an acute hepatic insult and associated with high 28-day mortality. The definition though lacks global consensus, excludes patients with known distinct entities such as acute liver failure and those with end-stage liver disease. The initial Systemic Inflammatory Response Syndrome (SIRS) because of cytokine storm in relation to acute insult and/or subsequent development of sepsis due to immunoparalysis leads to extrahepatic organ failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9887-5DOI Listing
September 2018
15 Reads

Multiple doses of hepatitis B recombinant vaccine for chronic hepatitis B patients with low surface antigen levels: a pilot study.

Hepatol Int 2018 Sep 7;12(5):456-464. Epub 2018 Aug 7.

Liver Research Center, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan City, Taiwan.

Background: Seroclearance of hepatitis B surface antigen (HBsAg) has been rarely achieved in the treatment of chronic hepatitis B (CHB) patients. We administered HBsAg-based recombinant vaccine in patients with low HBsAg concentrations.

Methods: Twenty hepatitis B e antigen-negative patients, with HBsAg < 1000 IU/ml, were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9890-xDOI Listing
September 2018
4 Reads

Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma.

Hepatol Int 2018 Sep 2;12(5):417-428. Epub 2018 Aug 2.

Department of Abdominal Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, 37 Guoxue Xiang, Chengdu, 610041, Sichuan, People's Republic of China.

Aims: Current evidence supporting the efficacy of transarterial chemoembolization (TACE) in Barcelona Clinic Liver Cancer (BCLC)-B hepatocellular carcinoma (HCC) is controversial. The aim of this systematic review was to compare the benefits of liver resection (LR) versus TACE in BCLC-B HCC.

Methods: We conducted a comprehensive literature review of the EMBASE, PubMed, Google Scholar, and Chinese Biomedical Literature databases for retrospective or prospective studies evaluating the efficacy of LR and TACE for the treatment of BCLC-B HCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9888-4DOI Listing
September 2018
5 Reads

Algorithms for managing coagulation disorders in liver disease.

Authors:
R Todd Stravitz

Hepatol Int 2018 Sep 31;12(5):390-401. Epub 2018 Jul 31.

Section of Hepatology, Hume-Lee Transplant Center, Virginia Commonwealth University, Richmond, VA, USA.

Patients with advanced liver disease have traditionally been considered at risk for bleeding complications. However, although bleeding in patients with cirrhosis frequently occurs due to complications of portal hypertension, research performed within the last 15 years has increasingly shown that hemostasis in patients with liver failure generally achieves a state of "rebalance", whereby compensatory systems restore a relatively neutral or even slightly pro-thrombotic state. Much recent clinical and in vitro research has, in fact, shown over-compensation, such that patients with acute and stable chronic liver failure may have a thrombotic tendency, which may participate in the progression of liver disease and cause systemic and portal thrombosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9886-6DOI Listing
September 2018
2 Reads

Global HBV burden: guesstimates and facts.

Hepatol Int 2018 Jul 27;12(4):315-329. Epub 2018 Jul 27.

Department of Medicine, Division of Gastroenterology and Hepatology, Endoscopy Unit, Alameda Health System-Highland Hospital Campus-Highland Care Pavilion 5th Floor, 1411 East 31st Street, Oakland, CA, 94602, USA.

Chronic hepatitis B virus infection (HBV) continues to pose a serious global health threat in many areas of the world, particularly in sub-Saharan Africa, the Western Pacific Region and areas of Eastern Europe. Endemicity is heterogeneous within and across regions owing to variable implementation of childhood and birth-dose vaccination programs, inconsistent screening of blood products, injection drug use, and poor education initiatives. This review aims to provide comprehensive up-to-date estimates of global seroprevalence of chronic HBV across six World Health Organization (WHO) regions, noting patterns of change over time and highlighting potential region-specific barriers to the diagnosis and elimination of HBV. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9884-8DOI Listing
July 2018
15 Reads

Clinical implication and viral mutation in basal core promoter/pre-core of hepatitis B virus C/D recombinant.

Hepatol Int 2018 Sep 24;12(5):447-455. Epub 2018 Jul 24.

Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, 510515, Guangzhou, China.

Background And Aim: Hepatitis B virus (HBV) C/D recombinant is predominant in Tibet in Western China. Although the geographical and ethnic distributions of the C/D recombinant have been described, the clinical implication and the characteristics of viral mutation in the basal core promoter (BCP)/pre-core (PC) region remain unclear.

Methods: A total of 174 chronic HBV carriers, including 115 with chronic hepatitis B, 45 with liver cirrhosis, and 14 with hepatocellular carcinoma, were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-018-9885-7DOI Listing
September 2018
5 Reads
2.470 Impact Factor